Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
出版年份 2019 全文链接
标题
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-08-14
DOI
10.3389/fonc.2019.00723
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment sequencing in metastatic colorectal cancer
- (2019) D.P. Modest et al. EUROPEAN JOURNAL OF CANCER
- Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients
- (2019) Qing-Gen Chen et al. Aging-US
- Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
- (2018) C Cremolini et al. ANNALS OF ONCOLOGY
- Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies
- (2018) Nele Boeckx et al. Clinical Colorectal Cancer
- Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
- (2018) Susanna Hegewisch-Becker et al. EUROPEAN JOURNAL OF CANCER
- Genomics and emerging biomarkers for immunotherapy of colorectal cancer
- (2018) Jakob Nikolas Kather et al. SEMINARS IN CANCER BIOLOGY
- A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
- (2018) Hironaga Satake et al. Oncotarget
- Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer
- (2018) Mayada A. Aljehani et al. JAMA Surgery
- Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer
- (2018) FRANK JORDAN et al. ANTICANCER RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
- (2018) Fotios Loupakis et al. BRITISH JOURNAL OF CANCER
- Immunodivergence in Metastatic Colorectal Cancer
- (2018) Carlos E. de Andrea et al. CANCER CELL
- Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer
- (2018) Olabisi Oluwabukola Coker et al. GUT
- Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)
- (2018) Herbert I. Hurwitz et al. ONCOLOGIST
- Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
- (2018) Dominiek Smeets et al. Nature Communications
- Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
- (2017) Sebastian Stintzing et al. EUROPEAN JOURNAL OF CANCER
- Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
- (2017) Paola Ulivi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
- (2017) Alan P. Venook et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Response rate and survival for patients with metastatic colorectal cancer from right-sided versus left-sided tumors, treated with first-line triplet chemotherapy with bevacizumab.
- (2017) Shouki Bazarbashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
- (2017) Michael S. Lee et al. Journal of the National Comprehensive Cancer Network
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- New Guideline on Managing Colorectal Cancer
- (2017) Cancer Discovery
- KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients
- (2017) De-cong Sun et al. Scientific Reports
- Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients
- (2017) Wen-Zhuo He et al. Journal of Cancer
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
- (2017) Sabine Tejpar et al. JAMA Oncology
- 185P Prognostic impact of tumor location and use of monoclonal antibodies in patients with metastatic colorectal cancer
- (2016) M. Nakamura et al. ANNALS OF ONCOLOGY
- Primary tumor location is an important predictive factor for wild-typeKRASmetastatic colon cancer treated with cetuximab as front-line bio-therapy
- (2016) Hsueh-Ju Lu et al. Asia-Pacific Journal of Clinical Oncology
- Colorectal Adenomas
- (2016) Williamson B. Strum NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients
- (2016) Jiao Yang et al. PLoS One
- E15Effectiveness of Cetuximab (Cet) and Bevacizumab (Bev) for metastatic colorectal cancer (mCRC) according to primary tumor location (PTL): findings from a ‘real-world’ retrospective analysis
- (2015) L. Calvetti et al. ANNALS OF ONCOLOGY
- Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
- (2015) A. Passardi et al. ANNALS OF ONCOLOGY
- RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) He Wen-zhuo et al. JNCI-Journal of the National Cancer Institute
- Colorectal cancer
- (2015) Herb Brody NATURE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Microbiota disbiosis is associated with colorectal cancer
- (2015) Zhiguang Gao et al. Frontiers in Microbiology
- RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) He Wen-zhuo et al. JNCI-Journal of the National Cancer Institute
- Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
- (2013) M. K. Boisen et al. ANNALS OF ONCOLOGY
- MMP-9 (Gelatinase B) Expression is Associated With Disease-Free Survival and Disease-Specific Survival in Colorectal Cancer Patients
- (2009) Riyad Bendardaf et al. CANCER INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now